Where does Supernus Pharmaceuticals's cash flow data come from?

Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$29.02M+24.7%	-$38.55M-102%	-$19.12M-130%	$64.5M+4.2%	$61.91M-16.2%
Depreciation and amortization	$97.31M+6.3%	$91.56M+7.2%	$85.39M+5.8%	$80.69M+0.8%	$80.05M-0.5%
Stock-based compensation	$33.46M+1.2%	$33.05M+6.5%	$31.03M+0.5%	$30.88M+3.2%	$29.93M+7.8%
Deferred income taxes	$15.11M+190%	$5.21M+138%	-$13.87M+21.6%	-$17.69M+5.1%	-$18.64M+7.4%
Impairment charges	——	$0—	$0—	$0—	$0—
Change in accounts receivable	$13.12M-41.2%	$22.3M+773%	$2.55M+122%	-$11.66M-457%	-$2.09M-0.8%
Change in inventories	$12.34M+64.5%	$7.5M+5,457%	$135K+101%	-$17.41M+6.1%	-$18.55M-17.3%
Change in accounts payable	-$28.46M-15.8%	-$24.57M-0.3%	-$24.49M-65.6%	-$14.79M+29.9%	-$21.1M-40.5%
Change in other assets	$32.98M+150%	$13.18M-22.9%	$17.08M+122%	$7.69M+48.2%	$5.19M-74.1%
Other working capital changes	——	——	——	——	——
Net gains (losses) on investments	——	——	——	——	-$2.25K-125%
Non-cash operating lease expense	——	——	——	——	$5.43M-0.4%
Change in fair value of contingent consideration	$20.15M-20.7%	$25.42M+232%	$7.66M+15.3%	$6.64M+190%	$2.29M+135%
Net cash from operating activities	——	——	——	$187.06M+14.0%	$164.15M-4.5%
Capital expenditures	$1.01M-24.4%	$1.34M+19.0%	$1.12M-5.9%	$1.2M+48.6%	$804K+10.9%
Purchases of investments	$435.82M-8.4%	$475.94M-10.4%	$531.15M-15.6%	$629.45M+2.7%	$612.87M-10.9%
Proceeds from maturities/sales of investments	$677.5M-12.5%	$774.48M-10.8%	$868.14M+58.5%	$547.7M+6.8%	$512.75M+2.8%
Net cash from investing activities	——	——	——	——	-$100.93M+46.8%
Proceeds from issuance of common stock	$49.24M+30.9%	$37.62M+4.7%	$35.94M+130%	$15.66M+11.5%	$14.04M-5.8%
Taxes paid for net share settlement	$5.44M+28.7%	$4.23M-18.4%	$5.19M+8.9%	$4.76M+1.0%	$4.72M+73.7%
Other financing activities	$4.16M-82.9%	$24.26M0.0%	$24.26M+8.3%	$22.4M+11.4%	$20.1M—
Net cash from financing activities	$39.64M+334%	$9.13M+40.6%	$6.49M+156%	-$11.5M-6.7%	-$10.78M-188%
Net increase (decrease) in cash	——	——	——	——	——
Income taxes paid	$15.37M-4.3%	$16.05M-44.1%	$28.69M-36.5%	$45.19M-15.0%	$53.19M-0.1%
Accrued product returns and rebates	$19.59M+357%	-$7.61M—	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	$32.98M+150%	$13.18M-22.9%	$17.08M+122%	$7.69M+48.2%	$5.19M-74.1%
Inventory write-downs	——	——	——	$8.35M-4.3%	$8.72M-2.1%
Investment Income Net Amortization Of Discount And Premium	——	——	——	——	——
Operating lease right-of-use asset amortization	——	——	——	——	$5.43M-0.4%
Other Noncash Income (Expense)	——	——	——	——	——
Payment For Contingent Consideration Liability Operating Activities	——	——	——	——	$4.9M—
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$677.5M-12.5%	$774.48M-10.8%	$868.14M+58.5%	$547.7M+6.8%	$512.75M+2.8%
Income Taxes Paid, Net	$15.37M-4.3%	$16.05M-44.1%	$28.69M-36.5%	$45.19M-15.0%	$53.19M-0.1%
Free cash flow	——	——	——	$185.87M+13.8%	$163.35M-4.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Supernus Pharmaceuticals's cash flow data come from?: Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.